Industry

Eli Lilly & Co. will pay an undisclosed amount to settle the lawsuit of the parents of a South Dakota boy who committed suicide...

Military.com reports that doctors from the Department of Veterans' Affairs are continuing to prescribe tranquilizers such as Valium and Xanax despite the VA's guidelines...

In 1956, Lou Lasagna was on his way to being the most famous doctor in the United States; an advocate for controlled clinical trials of both the safety and effectiveness of medication, as well as for a revision to the Hippocratic Oath to include a holistic and compassionate approach to medicine. Then, caught in the nexus of reason, regulation, and the pharmaceutical machine, his star fell.

Pfizer may face lawsuits regarding improper marketing of Neurontin after a Boston court reinstated lawsuits that had been denied class-action status by lower courts....

Journalist/humorist Jon Ronson’s TED talk “Strange Answers To The Psychopath Test” addresses the DSM, diseasing normality, faking mental illness, and the psychopathy of former CEO “Chainsaw” Al Dunlap. The Huffington Post, for their TED Weekends section, asked me for a reaction to Ronson’s talk—but then refused to print my blog because, a Huffington Post staffer emailed me, “the TED Weekends team said that the wording of the post was too strong.” Below is the original post.

In these days of sequestrations, budget cliffs, and congressional gridlock, everyone is feeling pressured to cut back, cut corners and find the most inexpensive way to accomplish anything and everything. For those of us who have been working so hard over the past decades, this leads to the obvious question, "can we afford recovery?" I mean, after all, it is usually cheaper to just give someone a drug than to invest in the time and effort needed to bring human spirits back alive to strive and thrive. So I decided to look at this question, from the vantage point of my own singular life.

The invitation from the London Review of Books to review Ben Goldacre’s Bad Pharma™ reads: “We were unsure, at first, what a review could add that isn’t already in the book – scrappy summaries and bits of praise are not for us. The book is of sufficient importance that the main thing is to get someone who knows what they’re talking about to present the material confidently... frame the discussion”. My head said it was inconceivable that the LRB wouldn’t take a review, even if it was at odds with the invitation to praise Bad Pharma. But my gut told me the inconceivable was about to take flesh.

Pete Early, author of Crazy, traces the history of NAMI, including its "complicated love-hate relationship with Dr. E. Fuller Torrey" and shift from his...

A review in BMC Psychiatry concludes that "Non-English language general psychiatry journals contribute substantially to the body of research. However, recognition, and in particular...

"Asheville psychiatrist Daniel Johnson didn't set out to transform his profession," says an article in North Carolina's Mountain Xpress, "But he’s now part of...

A review of 285 review articles from 10 top psychiatric and 2 general medicine journals finds that reviews in psychiatric journals were far less...

Vanda Pharmaceuticals, Inc., announced this week that its new antidepressant Tasimelteon failed to beat placebo in trials, and that it has hence ended its...

A lawsuit filed Wednesday in San Jose, California seeks federal approval for two class-action lawsuits representing all U.S. users of the antidepressant Zoloft, accusing...

Research from the Center for Clinical Trials at Johns Hopkins finds troubling differences between publicly available information on medications and the information that pharmaceutical...

In the business of clinical trials, the most valuable commodities are the research subjects. Filling clinical trials is hard, and filling them quickly is even harder. That’s why in 2000 a clinical investigator told the HHS Office of the Inspector General that research sponsors were looking for three things from research sites: “No. 1—rapid enrollment. No. 2 — rapid enrollment. No. 3 — rapid enrollment.”

This is the second in my new series, “Haiku for social change”, the first having appeared on my own blog page. Since this piece is about pharmacology and psychopharmacology, I think MIA is a good home for it.

One week before its court date, Pfizer settled with plaintiff Billy G. Bedsole Jr., who claims that Chantix triggered his suicidal thoughts and other...

In early 2009, antipsychotic fraud was making headlines.  Eli Lilly had announced in January that it would plead guilty to charges that it had...

Today I paid a visit to the Managing Director of Mylan Pharmaceuticals, Lloyd Price. Mylan is the company that manufactured the antidepressant Fluox1 which, according to the NZ government, is the most likely cause of my son's suicide. My dealings with Mylan in the time since Toran died have not been entirely fruitful.

The recent research scandals out of the University of Minnesota’s Department of Psychiatry may be alarming, but they are not new. Back in the 1990s, when the university was working its way towards a crippling probation by the National Institutes of Health (for yet another episode of misconduct (this time in the Department of Surgery), the Department of Psychiatry hosted two spectacular cases of research wrongdoing, both of which resulted in faculty members being disqualified from conducting research by the FDA.

In my recent Alternatives keynote I talked about mental health issues and our unjust prisons, including the shameful racism of the criminal justice system...

Ever since critics began asking questions about the death of Dan Markinson in a clinical trial at the University of Minnesota, the General Counsel for the university, Mark Rotenberg, has responded with a uniform message: the case has already been investigated many times, and no wrongdoing has ever been found. That's how Rotenberg responded to my article about the case in Mother Jones, and that's how he responded last week to the news that the Board of Social Work had issued a “corrective action” to the study coordinator for the clinical trial in which Markingson died.

The practice of medicine in our country is being swallowed whole by a snake. The snake started with the poor, the black, the brown; the already disenfranchised of the deep south and inner cities many years ago. It was an easy sell to the better-off taxpayers. Who wants to give up money to take care of poor people?

In the "agreement for corrective action" against CAFE study coordinator Jean Kenney last week, the Board of Social Work cited Kenney's failure to respond to "alarming voicemail messages" from family members of Dan Markingson. Presumably, the Board is referring to a message left by his mother, Mary Weiss, which warned, "Do we have to wait until he kills himself or someone else before anyone else does anything?" The failure of Kenney and Stephen Olson to take the warnings of Mary Weiss seriously has been one of the most disturbing aspects of this case. In a deposition for the lawsuit filed by Weiss, Kenney was questioned about her response. Here is an excerpt. (The initial questions come from Gale Pearson, an attorney for Mary Weiss.)

Following a record-setting spate of settlements, GlaxoSmithKline North America President Dierdre Connelly touts Glaxo's move away from a sales model that encourages the misbehavior...